And Technical Expertise
With a highly favorable legal and regulatory landscape in Europe, medical cannabis will be a high growth market: €300 M in 2018, to €2.8 B in 2024 to €15 B in 2029
There are promising new cannabinoid solutions under study for epilepsy, pain, spasticity, anxiety, and sleep
Researchers are looking for new treatments harnessing the properties of cannabinoids including treatments in oncology, ophthalmology, cardiovascular conditions, Autism and Down's Syndrome among others
With nationalized healthcare across Europe, governments want rapid and less costly solutions to societal health problems
Óskare Capital has identified a large number of companies in its dealflow pipeline with strong teams, disruptive IP and scalable companies (market and products)
ÓskareFund 1 fund target size is €150 M and AIFM domiciled in Dublin, Ireland (ICAV)
Management team based in Paris, France and UK
ESG compliant and will not invest in recreational cannabis
Fund will seek to have a balanced portfolio of early stage (Spin-off / Seed) and later stage (Series A to C) in innovative private and public companies
Investment geography: focus on Europe, with the opportunity to invest globally
Investments in science, services and solutions with high barriers to entry
Focus on scientific innovation and in generating solutions and tangible outcomes in the wellness and medical sectors for which there is strong scientific rationale to utilize cannabinoids
The fund will prioritize development of formulations combining cannabinoids with already approved pharmaceutical agents as well as new molecules
Invest In Solutions To Address
Unmet Needs In Health And Disease
The fund will invest in companies that have the greatest potential to create or enable availability of high quality, medical grade treatments for patients with unmet needs, including areas where traditional pharmaceutical agents have been ineffective or have a side effect profile limiting use for patients.
Engage In The Building Of The European
Medical Cannabinoid Ecosystem
Working closely with the founders of companies in our portfolio and in our Incubator, with our Industry Advisors, and with our network of collaborators we will work to realize the full economic opportunities of a robust cannabinoid ecosystem in Europe. In particular, we will capitalize on France’s strong agricultural and medical/pharma industry to become a leader in medical cannabinoid technology and ancillary services.
Provide An Attractive
Return On Investment
High Return Investments (HRI): Strong pipeline of early stage European Medical Cannabis companies (Seed and Series A), longer term and higher risk investments. Target of 60-70% in Early Stage (Spin-Off, Seed, Series A) and 30-40% in later stage (Series B+).
Balanced Returns with Upside (BRU): Diverse pipeline of later stage companies (some publicly traded) that have more mature product pipelines and revenues, shorter term prospects for exit (2-4 years).
Risk Profile: Mix between longer term (pharma and healthcare) investments that can provide >10X multiples with companies operating with exit prospects 2-4 years after initial investment with a majority of investments in private companies.